Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 2,033–2,040 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
ImmunityBio Inc. ANKTIVA - (ResQ201A-NSCLC) Non-Small Cell Lung Cancer BLA Filing Trial Planned Intravenous Oncology
ImmunityBio Inc. Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055) NSCLC, Various tumors Phase 2b Data Released Intravenous Oncology
ImmunityBio Inc. ANKTIVA NMIBC Papillary Disease BLA Filing Ongoing Intravenous Oncology
ImmunityBio Inc. t-haNK and Anktiva (N-803) - (QUILT-88) Pancreatic cancer Phase 2 Intravenous Oncology
ImmunityBio Inc. ANKTIVA (nogapendekin alfa inbakicept) - (QUILT-3.055) 2L Non-Small Cell Lung Cancer(NSCLC) Phase 3 Ongoing Intravesical Oncology
ImmunityBio Inc. Anktiva (N-803) and Cytokine-enriched natural killer (m-ceNK) cells Acute myeloid leukemia (AML) Phase 2 Intravenous Oncology
ImmunityBio Inc. ANKTIVA - (ResQ201A-NSCLC) Non-Small Cell Lung Cancer BLA Filing Trial Planned Intravenous Oncology
ImmunityBio Inc. Anktiva (N-803) Lung-MAP Non-small cell lung cancer (NSCLC) Phase 2/3 Intravenous Oncology